- Home
- HFBL vs MAIA Comparison
HFBL vs MAIA Comparison
Compare HFBL & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HFBL
- MAIA
- Stock Information
- Founded
- HFBL 1924
- MAIA 2018
- Country
- HFBL United States
- MAIA United States
- Employees
- HFBL N/A
- MAIA N/A
- Industry
- HFBL Savings Institutions
- MAIA Biotechnology: Pharmaceutical Preparations
- Sector
- HFBL Finance
- MAIA Health Care
- Exchange
- HFBL Nasdaq
- MAIA Nasdaq
- Market Cap
- HFBL 41.6M
- MAIA 44.9M
- IPO Year
- HFBL N/A
- MAIA 2022
- Fundamental
- Price
- HFBL $14.54
- MAIA $1.44
- Analyst Decision
- HFBL
- MAIA
- Analyst Count
- HFBL 0
- MAIA 0
- Target Price
- HFBL N/A
- MAIA N/A
- AVG Volume (30 Days)
- HFBL 1.8K
- MAIA 980.6K
- Earning Date
- HFBL 10-23-2025
- MAIA 11-11-2025
- Dividend Yield
- HFBL 3.70%
- MAIA N/A
- EPS Growth
- HFBL 35.20
- MAIA N/A
- EPS
- HFBL 1.47
- MAIA N/A
- Revenue
- HFBL $21,720,000.00
- MAIA N/A
- Revenue This Year
- HFBL N/A
- MAIA N/A
- Revenue Next Year
- HFBL N/A
- MAIA N/A
- P/E Ratio
- HFBL $9.94
- MAIA N/A
- Revenue Growth
- HFBL 10.10
- MAIA N/A
- 52 Week Low
- HFBL $11.75
- MAIA $1.26
- 52 Week High
- HFBL $14.86
- MAIA $3.48
- Technical
- Relative Strength Index (RSI)
- HFBL 71.13
- MAIA 44.29
- Support Level
- HFBL $14.00
- MAIA $1.26
- Resistance Level
- HFBL $14.20
- MAIA $1.54
- Average True Range (ATR)
- HFBL 0.11
- MAIA 0.09
- MACD
- HFBL 0.02
- MAIA -0.01
- Stochastic Oscillator
- HFBL 72.41
- MAIA 28.92
About HFBL Home Federal Bancorp Inc. of Louisiana
Home Federal Bancorp Inc of louisiana operates as a bank holding company. It is a federally chartered stock savings bank, which provides financial services to individuals, corporate entities, and other organizations. Its core activities consist of attracting deposits from the general public and using those funds to originate loans to the residential, commercial and multi-family segments. The company also invests securities held-to-maturity and securities available for sale.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.